Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Clear-Cell Renal Cell Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT05444933
What this trial is testing

Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.

Who this might be right for
Advanced Renal Cell Carcinoma
Ipsen 252
Testing effectiveness (Phase 2)Study completedNCT00719264
What this trial is testing

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Who this might be right for
CarcinomaAdenocarcinomaRenal Cell+2 more
Novartis Pharmaceuticals 365
Not applicableLooking for participantsNCT03747133
What this trial is testing

SABR for Renal Tumors

Who this might be right for
Renal Tumor
University Health Network, Toronto 90
Testing effectiveness (Phase 2)Study completedNCT00502307
What this trial is testing

Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal Cell
AVEO Pharmaceuticals, Inc. 272
Testing effectiveness (Phase 2)Looking for participantsNCT05824975
What this trial is testing

Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more
GI Innovation, Inc. 358
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Early research (Phase 1)Active Not RecruitingNCT05238883
What this trial is testing

HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Who this might be right for
Gastric CancerRenal Cell CarcinomaMelanoma+6 more
HiFiBiO Therapeutics 72
Testing effectiveness (Phase 2)Ended earlyNCT05714553
What this trial is testing

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Who this might be right for
Advanced CancerAdvanced Solid TumorNeoplasm Malignant+14 more
NuCana plc 19
Testing effectiveness (Phase 2)Ended earlyNCT03185182
What this trial is testing

Diagnostic Imaging for Clear Cell Renal Cell Carcinoma

Who this might be right for
Clear Cell Renal Cell Carcinoma
Region Skane 5
Early research (Phase 1)Ended earlyNCT04234113
What this trial is testing

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Who this might be right for
Thyroid CancerRenal Cell CarcinomaNon Small Cell Lung Cancer+16 more
SOTIO Biotech AG 115
Early research (Phase 1)Looking for participantsNCT05433142
What this trial is testing

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Who this might be right for
Clear Cell Renal Cell Carcinoma
Xencor, Inc. 307
Testing effectiveness (Phase 2)WithdrawnNCT03149159
What this trial is testing

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

Who this might be right for
Clear Cell Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
Medical University of South Carolina
Not applicableStudy completedNCT00743054
What this trial is testing

MicroRNA Expression in Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal Cell
Sun Yat-sen University 50
Not applicableStudy completedNCT00895674
What this trial is testing

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Who this might be right for
Carcinoma, Renal CellCarcinoma, Renal Cell (Advanced)
Bayer 2,840
Testing effectiveness (Phase 2)Study completedNCT00445042
What this trial is testing

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

Who this might be right for
Carcinoma, Renal Cell
The Methodist Hospital Research Institute 71
Early research (Phase 1)Study completedNCT02890069
What this trial is testing

PDR001 in Combination With LCL161, Everolimus or Panobinostat

Who this might be right for
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Novartis Pharmaceuticals 298
Testing effectiveness (Phase 2)Looking for participantsNCT03972657
What this trial is testing

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)Clear Cell Renal Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals 345
Testing effectiveness (Phase 2)Ended earlyNCT01391130
What this trial is testing

LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Who this might be right for
Metastatic Clear Cell Renal Cell Carcinoma
Eli Lilly and Company 110
Testing effectiveness (Phase 2)UnknownNCT03544723
What this trial is testing

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Who this might be right for
Solid TumorLymphoma
MultiVir, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT03945773
What this trial is testing

Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

Who this might be right for
Locally Advanced or Metastatic Renal Cell Carcinoma
Ipsen 127
Next Page